A PERSONALIZED APPROACH TO ADJUVANT CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER AFTER RADICAL SURGICAL TREATMENT BASED ON MOLECULAR MARKERS OF CHEMOSENSITIVITY
L. A. Efteev,
E. O. Rodionov,
S. V. Miller,
S. A. Tuzikov,
M. M. Tsyganov,
I. V. Deryusheva,
N. V. Litvyakov,
I. G. Frolova https://doi.org/10.21294/1814-4861-2019-18-5-108-112
Abstract
Despite advances in the treatment of non-small cell lung cancer (NSC LC), prognosis of advanced lung cancer is extremely poor. The search for additional treatment options to prevent local recurrence and distant metastases is of great importance. Monoresistance genes, such as ABCC5, BRCA1, RRM1, ERCC1, TOP1, TOP2a, TUBB3, and TYMS play a significant role in tumor sensitivity to chemotherapy for NSC LC. The expression levels of these genes in tumor tissue should be assessed for personalization of adjuvant chemotherapy in patients with NSC LC.
Case description. We present a clinical case of a 65-year-old patient diagnosed with non-small cell lung cancer who underwent extended combined surgery followed by 4 courses of personalized adjuvant chemotherapy. The expression levels of monoresistance genes (ABCC5, RRM1, ERCC1, TOP1, TOP2a, TUBB3, BRCA 1 and TYMS) determined by reverse-transcriptase quantitative real-time PCR (RTqPCR) were used as predictive markers of response to adjuvant chemotherapy regimen.
Conclusion. Our case report demonstrated the feasibility of performing organ-preserving surgery followed by personalized adjuvant chemotherapy based on the expression levels of monoresistance genes as predictive markers of benefit from adjuvant chemotherapy.
Keywords
combination treatment,
non-small cell lung cancer,
personalized chemotherapy,
monoresistance genes,
adjuvant chemotherapy
Supporting agencies: The study was supported by the program «Participants of the Youth Science and Innovation Competition» of the Foundation for Assistance to the Development of Small Enterprises in the Scientific and Technical Field. Agreement No. 11783 of GU / 2017 dated July 3, 2017
About the Authors
L. A. Efteev
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Leonid A. Efteev, MD, Junior Researcher, Thoracic Department
5, Kooperativny Street, 634009-Tomsk
E. O. Rodionov
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences;
Siberian State Medical University
Russian Federation
Russian Federation
Evgenii O. Rodionov, MD, PhD, Senior Researcher, Thoracic Department
5, Kooperativny Street, 634009-Tomsk,
2, Moskovskiy Tract, 634050-Tomsk
Researcher ID (WOS): B-7280-2017
Author ID (Scopus): 57189622130
S. V. Miller
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Sergey V. Miller, MD, DSc, Leading Researcher, Thoracic Department
5, Kooperativny Street, 634009-Tomsk
Researcher ID (WOS): C-8970-2012
Author ID (Scopus): 56525429400
S. A. Tuzikov
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences;
Siberian State Medical University
Russian Federation
Russian Federation
Sergey A. Tuzikov, MD, DSc, Professor, Head of Thoracic Department, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
5, Kooperativny Street, 634009-Tomsk,
2, Moskovskiy Tract, 634050-Tomsk
Researcher ID (WOS): D-1176-2012
Author ID (Scopus): 6507842873
M. M. Tsyganov
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Matvey M. Tsyganov, PhD, Researcher, Laboratory of Viral Oncology
5, Kooperativny Street, 634009-Tomsk
Researcher ID (WOS): A-7212-2014
Author ID (Scopus): 55366377400
I. V. Deryusheva
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Irina V. Deriusheva, Junior Researcher, Laboratory of Viral Oncology
5, Kooperativny Street, 634009-Tomsk
Researcher ID (WOS): Q-5607-2017
N. V. Litvyakov
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences;
Tomsk State University
Russian Federation
Russian Federation
Nikolai V. Litviakov, DSc, Head of Laboratory of Viral Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
5, Kooperativny Street, 634009-Tomsk,
36, Lenina Prospect, 634050-Tomsk
Researcher ID (WOS): C-3263-2012
Author ID (Scopus): 6506850698
I. G. Frolova
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Irina G. Frolova, MD, DSc, Professor, Head of the Diagnostic Imaging Department
5, Kooperativny Street, 634009-Tomsk
Researcher ID (WOS): C-82122012
Author ID (Scopus): 7006413170
References
1. Choynzonov E.L., Zhuikova L.D., Ananina A.O., Polishchuk T.V., Pikalova L.V. Survival of lung cancer patients residing in Tomsk region (2004–2013). Siberian Journal of Oncology. 2017; 16(4): 5–10. (in Russian). doi: 10.21294/1814-4861-2017-16-4-5-10.
2. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1; 136(5): E359–E386. doi: 10.1002/ijc.29210.
3. Popova N.O., Shatalova V.A., Simolina E.I., Kravchuk T.L., Dudnikova E.A., Podoplekin D.M., Goldberg V.E. ] Longterm follow-up of a patient with metachronous lung cancer. Siberian Journal of Oncology. 2011; 4: 75–77. (in Russian).
4. Postmus P.E., Kerr K.M., Oudkerk M., Senan S., Waller D.A., Vansteenkiste J., Escriu C., Peters S.; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol. 2017 Jul 1; 28(SUPPL_4): iv1–iv21. doi: 10.1093/annonc/mdx222.
5. Zhang Q., Zhu X., Zhang L., Sun S., Huang J., Lin Y. A prospective study of biomarker-guided chemotherapy in patients with nonsmall cell lung cancer. Cancer Chemother Pharmacol. 2014; 74(4): 839–846. doi: 10.1007/s00280-014-2513-x.
6. Olaussen K.A., Postel-Vinay S. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Ann Oncol. 2016 Nov 1; 27(11): 2004–2016. doi: 10.1093/annonc/mdw321.
Review
For citations:
Efteev L.A., Rodionov E.O., Miller S.V., Tuzikov S.A., Tsyganov M.M., Deryusheva I.V., Litvyakov N.V., Frolova I.G. A PERSONALIZED APPROACH TO ADJUVANT CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER AFTER RADICAL SURGICAL TREATMENT BASED ON MOLECULAR MARKERS OF CHEMOSENSITIVITY. Siberian journal of oncology. 2019;18(5):108-112. (In Russ.) https://doi.org/10.21294/1814-4861-2019-18-5-108-112
Views:
832
Email this article 
